BACKGROUND: There has been growing interest in providing clinical trial participants with study results yet only limited information exists regarding the process and impact of sharing results. We sought to evaluate patient perceptions of how results had been shared from a large randomized cooperative group trial, and the impact of learning results. PATIENTS AND METHODS: A subset of women who participated in NCCTG 9831 (A Phase III Trial of Adjuvant Chemotherapy with or without Trastuzumab for Women with HER2-positive Breast Cancer) were mailed surveys after the preliminary study results were released to the public and mailed to participants. RESULTS: One hundred and 67 of 228 surveys sent (73%) were returned; 61% reported receiving trastuzumab on study; 4% reported recurrent disease. Ninety-five percent of participants were glad they received results; 81% were satisfied with how results were shared; 23% were more anxious after learning the results. Sixty-nine percent correctly interpreted the results. Logistic regression revealed that satisfaction with the process of receiving results was associated with satisfaction with treatment (P = 0.04), and increased anxiety was associated with dissatisfaction with treatment (0.02), incorrect interpretation of results (0.04), and not having received trastuzumab (P < 0.0001). CONCLUSION: Sharing results directly with study participants is met with overwhelmingly favorable responses from patients, although some may not initially understand the findings. The potential for increased anxiety should be considered, and psychosocial support may be required by some. A plan to share results should be routinely and prospectively considered in the design of cancer clinical trials.
RCT Entities:
BACKGROUND: There has been growing interest in providing clinical trial participants with study results yet only limited information exists regarding the process and impact of sharing results. We sought to evaluate patient perceptions of how results had been shared from a large randomized cooperative group trial, and the impact of learning results. PATIENTS AND METHODS: A subset of women who participated in NCCTG 9831 (A Phase III Trial of Adjuvant Chemotherapy with or without Trastuzumab for Women with HER2-positive Breast Cancer) were mailed surveys after the preliminary study results were released to the public and mailed to participants. RESULTS: One hundred and 67 of 228 surveys sent (73%) were returned; 61% reported receiving trastuzumab on study; 4% reported recurrent disease. Ninety-five percent of participants were glad they received results; 81% were satisfied with how results were shared; 23% were more anxious after learning the results. Sixty-nine percent correctly interpreted the results. Logistic regression revealed that satisfaction with the process of receiving results was associated with satisfaction with treatment (P = 0.04), and increased anxiety was associated with dissatisfaction with treatment (0.02), incorrect interpretation of results (0.04), and not having received trastuzumab (P < 0.0001). CONCLUSION: Sharing results directly with study participants is met with overwhelmingly favorable responses from patients, although some may not initially understand the findings. The potential for increased anxiety should be considered, and psychosocial support may be required by some. A plan to share results should be routinely and prospectively considered in the design of cancer clinical trials.
Authors: N T Brewer; J T Defrank; W K Chiu; J G Ibrahim; C M Walko; P Rubin; O A Olajide; S G Moore; R E Raab; D R Carrizosa; S W Corso; G Schwartz; J M Peppercorn; H L McLeod; L A Carey; W J Irvin Journal: Public Health Genomics Date: 2014-01-22 Impact factor: 2.000
Authors: Ann H Partridge; Karen Sepucha; Anne O'Neill; Kathy D Miller; Christine Motley; Ramona F Swaby; Bryan P Schneider; Chau T Dang; Donald W Northfelt; George W Sledge Journal: JAMA Oncol Date: 2015-06 Impact factor: 31.777
Authors: J Mancini; D Genre; F Dalenc; J-M Ferrero; P Kerbrat; A-L Martin; H Roché; F Maylevin; C Tarpin; P Viens; J Genève; C Julian-Reynier Journal: Br J Cancer Date: 2010-03-02 Impact factor: 7.640
Authors: Ebony B Bookman; Corina Din-Lovinescu; Bradford B Worrall; Teri A Manolio; Siiri N Bennett; Cathy Laurie; Daniel B Mirel; Kimberly F Doheny; Garnet L Anderson; Kate Wehr; Richard Weinshilboum; Donna T Chen Journal: Genome Med Date: 2013-01-30 Impact factor: 11.117